Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | AC Immune SA | 25 |
| 2 | Genentech Inc | 22 |
| 3 | Washington University in St. Louis | 14 |
| 4 | University of Washington | 9 |
| 5 | Denali Therapeutics Inc | 5 |
| 6 | Tenaya Therapeutics Inc | 5 |
| 7 | University of California, San Diego | 5 |
| 8 | Genting Taurx Diagnostic Centre Sdn Bhd | 4 |
| 9 | Genzyme Corp | 4 |
| 10 | University of California Berkeley | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 186 |
| 2 | A61K | Medicinal preparations | 178 |
| 3 | C07K | Peptides | 73 |
| 4 | G01N | Investigating / analysing materials | 68 |
| 5 | C07D | Heterocyclic compounds | 51 |
| 6 | A61B | 29 | |
| 7 | C12N | Microorganisms, enzymes | 26 |
| 8 | A23L | Foods and beverages (general) | 21 |
| 9 | G16H | Digital health, healthcare informatics | 21 |
| 10 | G06N | 17 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Claude M. Wischik | University of Aberdeen | 15 |
| 2 | Charles R. Harrington | University of Aberdeen | 14 |
| 3 | Gernot Riedel | University of Aberdeen | 10 |
| 4 | John M. D. Storey | University of Aberdeen | 6 |
| 5 | B. Schelter | University of Aberdeen | 5 |
| 6 | Peter Bentham | TauRx (United Kingdom) | 5 |
| 7 | Diego Monti | Institute of Molecular Science and Technologies | 2 |
| 8 | Franz Theuring | Charité - Universitätsmedizin Berlin | 4 |
| 9 | Helen Shiells | TauRx (United Kingdom) | 4 |
| 10 | Karima Schwab | Charité - Universitätsmedizin Berlin | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Methylene blue as an inhibitor of superoxide generation by xanthine oxidase | 1991 | 224 | Sulfur Compounds in Biology |
| Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial | 2017 | 218 | Dementia and Cognitive Impairment Research |
| Binding, Aggregation and Photochemical Properties of Methylene Blue in Mitochondrial Suspensions | 2004 | 165 | Nanoplatforms for cancer theranostics |
| Interactions of Methylene Blue with Human Disulfide Reductases and Their Orthologues from<i>Plasmodium falciparum</i> | 2007 | 162 | Genomics, phytochemicals, and oxidative stress |
| A new assay method for lipid peroxides using a methylene blue derivative. | 1985 | 143 | Electrochemical sensors and biosensors |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Hydromethylthionine Mesylate?
Which organizations hold the most patents for this compound?
What are the primary research areas covered by patents for Hydromethylthionine Mesylate?
Who are the leading researchers publishing on this compound?
What is the recent patent and publication activity for this compound?